Dong-A St - Asset Resilience Ratio
Dong-A St (170900) has an Asset Resilience Ratio of 9.52% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 170900 total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how Dong-A St's Asset Resilience Ratio has changed over time. See Dong-A St shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Dong-A St's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 170900 market cap.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0% |
| Short-term Investments | ₩135.55 Billion | 9.52% |
| Total Liquid Assets | ₩135.55 Billion | 9.52% |
Asset Resilience Insights
- Limited Liquidity: Dong-A St maintains only 9.52% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Dong-A St Industry Peers by Asset Resilience Ratio
Compare Dong-A St's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 9.09% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.02% |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456 |
Drug Manufacturers - Specialty & Generic | 0.01% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557 |
Drug Manufacturers - Specialty & Generic | 0.29% |
|
Cronos Group Inc
TO:CRON |
Drug Manufacturers - Specialty & Generic | 69.94% |
Annual Asset Resilience Ratio for Dong-A St (2013–2024)
The table below shows the annual Asset Resilience Ratio data for Dong-A St.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 8.41% | ₩117.02 Billion ≈ $79.31 Million |
₩1.39 Trillion ≈ $943.16 Million |
+2.58pp |
| 2023-12-31 | 5.83% | ₩73.67 Billion ≈ $49.93 Million |
₩1.26 Trillion ≈ $856.88 Million |
+3.69pp |
| 2022-12-31 | 2.14% | ₩24.75 Billion ≈ $16.77 Million |
₩1.16 Trillion ≈ $784.57 Million |
-7.71pp |
| 2021-12-31 | 9.85% | ₩109.89 Billion ≈ $74.47 Million |
₩1.12 Trillion ≈ $756.29 Million |
-1.20pp |
| 2020-12-31 | 11.05% | ₩108.34 Billion ≈ $73.42 Million |
₩980.67 Billion ≈ $664.58 Million |
+9.83pp |
| 2019-12-31 | 1.22% | ₩12.28 Billion ≈ $8.32 Million |
₩1.01 Trillion ≈ $683.63 Million |
+1.14pp |
| 2018-12-31 | 0.07% | ₩705.99 Million ≈ $478.44K |
₩948.67 Billion ≈ $642.90 Million |
-0.18pp |
| 2017-12-31 | 0.25% | ₩2.29 Billion ≈ $1.55 Million |
₩899.72 Billion ≈ $609.73 Million |
+0.14pp |
| 2016-12-31 | 0.11% | ₩1.18 Billion ≈ $796.28K |
₩1.07 Trillion ≈ $722.83 Million |
-0.10pp |
| 2015-12-31 | 0.21% | ₩2.20 Billion ≈ $1.49 Million |
₩1.06 Trillion ≈ $720.75 Million |
-1.77pp |
| 2014-12-31 | 1.98% | ₩21.39 Billion ≈ $14.50 Million |
₩1.08 Trillion ≈ $733.16 Million |
+0.63pp |
| 2013-12-31 | 1.34% | ₩12.51 Billion ≈ $8.48 Million |
₩931.72 Billion ≈ $631.41 Million |
-- |
About Dong-A St
Dong-A ST Co., Ltd. develops, manufactures, and markets pharmaceutical products in South Korea and internationally. It offers various ethical drugs, including Clofazimine cap. For lepromatous leprosy; Closerin Cap for active pulmonary and extra-pulmonary tuberculosis; Eporon inj./PFS for anemia associated with chronic renal failure; Gemcit inj. to treat non-small cell lung, pancreatic, breast, bl… Read more